[Ustekinumab in Crohn’s disease]
Secco A, Alfie V, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A.
Record ID 32018001582
Spanish
Original Title:
Ustekinumab para enfermedad de Crohn con fracaso a tratamiento convencional
Authors' recommendations:
No evidence directly comparing ustekinumab with other biologic agents in moderate-severe Chrohn’s disease has been found. High-quality evidence shows that ustekinumab, in patients with moderate-severe Chrohn’s disease, with no response or intolerance to conventional treatment and/or treatment with anti-TNF biologic agents, is superior to placebo plus standard therapy in achieving remission after one year of treament, as measured by a validated disease activity scale. Extension studies show that efficacy and safety are maintained over time, at three years of follow-up. Low-quality evidence from indirect comparisons suggests that ustekinumab would be similar to other biologic agents in treating these patients.
The clinical practice guidelines consider ustekinumab as one of the therapeutic options in patients who failed with conventional treatment or anti-TNF biologic agents. The United States and Europe private and public health funders consulted cover this and other biologic drugs for this indication; however, they do not recommend one over the other. Most Latin America coverage policies consulted, do not mention or do not cover ustekinumab for Crohn’s disease. Some guidelines and coverage policies mention that treatment choice should be case by case and in those patients for whom more than one option is adequate, the costs of choosing one treatment should be considered.
No local economic studies on the cost-effectiveness of this technology for these indications assessed have been found.
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Crohn Disease
- Ustekinumab
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.